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Background: Detection of retinal β-amyloid (Aβ) peptide accumulation is a novel
diagnostic method for Alzheimer’s disease (AD), but there is, as yet, no conclusive
evidence of its accuracy.
Aim: To identify the diagnostic accuracy of pathological retinal Aβ detection for AD by a
meta-analytic approach.
Methods: Electronic and reference searches were conducted to identify studies related
to the diagnostic effects of retinal Aβ detection in AD that met pre-defined inclusion
criteria. The QUADAS-2 tool was employed to assess the risk of bias, and Review
Manager plus the Open Meta-Analyst were used to perform the data analysis.
Results: From 493 unduplicated reports, five studies with small sample sizes were
included in this review. Six staining methods were employed. The eligible studies
showed extremely broad ranges of sensitivity (0–1.00) and specificity (0.50–1.00) with
substantial heterogeneity. The estimates of positive likelihood ratio (PLR), negative
likelihood ratio (NLR), diagnostic odds ratio (DOR) were also extremely varied (from 0.71
to 11.57 for PLR, from 0.04 to 1.11 for NLR, and from 0.69 to 297.00 for DOR).
Conclusions: The limited number of eligible studies and their methodological
heterogeneity make it impossible to come to a conclusion whether pathological retinal
Aβ detection is an effective diagnostic tool for AD. More studies, especially large surveys
investigating retina Aβ load with quantitative methods among consecutive or random
samples, are needed to determine the accuracy of Aβ detection for diagnosing AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive brain disorder that damages brain cells, which leads to
memory loss and other brain dysfunctions (Kandimalla et al., 2013; Ramesh et al., 2014; Jansen
et al., 2015). Globally, AD is the most frequent neurodegenerative disorder and accounts for
50–70% cases of dementia (Winblad et al., 2016). It was estimated that dementia affected 46.8
million individuals and cost 818 billion USD worldwide in 2015 (Alzheimer’s Association, 2015).
At present, the definitive diagnosis of AD still depends on an autopsy of the brain, by
the histopathological identification of amyloid precursor protein’s (APP) hallmark proteolytic
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products, β-amyloid (Aβ) peptides, and intracellular
neurofibrillary tangles (Sisodia and Price, 1995; Hardy and
Selkoe, 2002). According to the Aβcascade hypothesis, the
principal event in the pathogenesis of AD is the accumulation of
Aβ plaques in the brain (Hardy and Selkoe, 2002; Jack et al., 2010;
Karran et al., 2011). Thus, massive attention has been paid to the
detection of Aβ accumulation among common AD biomarkers.
As an extension of the central nervous system, the retina is
easily accessed through widely used imaging techniques such
as scanning laser ophthalmoscopy (SLO) and optical coherence
tomography (OCT). Therefore the retina is likely to be an ideal
target for non-invasive imaging of AD in vivo, provided that
Aβ plaques accumulate in the retinas of AD patients and that
their properties are consistent with those in the brain (Koronyo
et al., 2012). As a consequence, recent studies have focused on
identifying Aβ in retina as a technique to facilitate the diagnosis
of AD in humans and in animal models (Koronyo-Hamaoui et al.,
2011; Koronyo et al., 2012).
Koronyo-Hamaoui et al. (2011) stated that they had
demonstrated Aβ accumulation in postmortem retinas from AD
patients, while Schön et al. (2012) could not detect any Aβ plaques
in the retinas of AD patients. Obviously, the interaction between
retina Aβ and brain Aβ has not been articulately illuminated.
Hence, the importance of the postmortem tests for Aβ in the
retina would be to guide future research concerning non-invasive
retinal Aβ detection techniques. In this meta-analysis, we aimed
to determine the accuracy of pathological Aβ detection for
diagnosing AD.
MATERIALS AND METHODS
Search Strategy
We searched BIOSIS Previews (ISI Web of Knowledge), Current
Contents Connect (ISI Web of Knowledge), EMBASE(Ovid
SP), MEDLINE (Ovid SP), Science Citation Index (ISI Web of
Knowledge), and PsycINFO (Ovid SP) up to March 16, 2016. We
considered using Chinese-language databases (CNKI, CQVIP,
Wanfang), however, we decided not to use these databases in our
formal search since no relevant reports were identified among
them in the preliminary searches. A structured search strategy
was devised for each platform using following key words and
their abbreviation and MeSH synonyms: (1) Alzheimer’s disease;
(2) β-amyloid; (3) retina; (4) pathologic or histologic or immune
or fluorescent test. Detailed electronic search strategies were
presented in Supplementary Table S1. For reference lists, all
eligible published reports were scanned for further possible titles.
This procedure was repeated until no new titles were found
(Greenhalgh and Peacock, 2005; Horsley et al., 2011).
Selection of Studies
Two review authors (JJ, HW) independently performed
assessments of titles and abstracts to identify potentially eligible
studies for full-text reviews. They then performed further
assessment of full manuscripts against the inclusion criteria,
which were as follows: (1) the target condition is AD, which
should be confirmed by the neuropathological tests of brain
tissue, and neuropathological information based on the Braak
(Braak et al., 2006), the Consortium to Establish a Registry
for Alzheimer’s Disease (CERAD) (Mirra et al., 1991), or the
National Institute for Aging and the Ronald and Nancy Reagan
Institute for the Alzheimer’s Association (NIA-RIA) criteria (Ball
et al., 1997), which are all recognized as acceptable confirmations
of AD dementia (Murayama and Saito, 2004); (2) the index test
in this review is the presence of Aβin the retinas, assessed by any
kinds of routine staining; (3) we only considered cross-sectional
studies because the index test is usually conducted posthumously
due to its invasive nature. When necessary, a third review author
(WL) acted as an arbitrator to resolve disagreements that could
not be resolved through discussion by the original two reviewers.
When the same data set was presented in two or more papers,
the primary paper with the largest number of patients or the
most informative data, was included. At each time point of
this selection process, the numbers of studies selected were
detailed in a Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) flow diagram (Moher et al., 2009).
Data Extraction and Quality Assessment
The two review authors independently extracted the data
on study characteristics, including the following information:
bibliographic details of the primary paper, patient-sampling
details, basic patient characteristics, details of the index test,
target conditions, reference standards, and data for the 2 × 2
tables. Again, a third review author acted as an arbitrator to settle
disagreements when necessary.
The investigators identified the methodological quality of
each study using QUADAS-2 (Whiting et al., 2011). Instead
of applying QUADAS-2 data to forming a summary quality
score, a narrative summary was generated that included studies
that found a high/low/unclear risk of bias and concerns with
regard to applicability. We refined the original QUADAS-
2 tools to meet the needs of this systematic review. Since
the index test in this review is qualitative, the item ‘If
a threshold was used, was it pre-specified?’ in the index
test domain was recognized as not applicable. Additionally,
the question ‘Was there an appropriate interval between
index test and reference standard?’ in the flow and timing
domain was not used because we only included cross-sectional
studies.
Statistical Analysis
The data of the 2 × 2 tables for the index test performance
(True positive, false negative, false positive, true negative) were
employed to calculate the accuracy estimates of each primary
study. By utilizing Review Manager version 5.3, we calculated
each data set’s sensitivity (Sen), specificity (Spe), and 95%
confidence interval (95% CI). Using Open Meta-Analyst build
5.26.14, we estimated each study’s positive likelihood ratio
(PLR), negative likelihood ratio (NLR), diagnostic odds ratio
(DOR), and 95% CI, respectively, with a random effect approach.
The estimate results were presented graphically in a forest
plot. Additionally, the sensitivity and specificity estimates with
their 95% CI among those studies were also presented in a
receiver operating characteristic (ROC) space. We planned not
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to compute or plot the pooled point estimates of Sen and Spe
with the hierarchical summary ROC curve (HSROC) method
(Rutter and Gatsonis, 2001) or the bivariate random effects
approach (Reitsma et al., 2005), since threshold effects were
usually not identified in a qualitative index test. Sensitivity
analyses were performed with or without inclusion of possible
AD and probable AD.
Heterogeneity Investigation and
Reporting Bias Assessment
The potential sources of heterogeneity include patient factors,
differing assay methods for the index test, variety in reference
standards, how the primary studies operated, and so forth.
All of these factors may affect the diagnostic accuracy of
the test. Statistical heterogeneity was assessed via visual
inspection of the forest plot and the ROC plot and by
utilizing I2 alongside the χ2 P-value. If I2 was greater than
or equal to 50% with a statistically significant χ2 result, we
considered the data to have substantial levels of heterogeneity
(Higgins and Green, 2008). When significant heterogeneity
was identified, we planned to investigate the reasons for
heterogeneity by the meta-regression approach and visual
inspection. Due to current uncertainty about how reporting-
bias operates in test accuracy studies, we did not investigate
it by interpretation of funnel plots or other existing analysis
tools.
RESULTS
Eligible Studies
From 1,011 records identified via electronic searching, only
five eligible studies were eventually included (Koronyo-Hamaoui
et al., 2011; Schön et al., 2012; Ho et al., 2014; Tsai et al., 2014; La
Morgia et al., 2016). The literature selection process is detailed in
Figure 1. Among five included studies, six staining methods were
employed, including Congo red along, Aβ antibody alone, Aβ
antibody plus curcumin, Aβ antibody plus FSB [(trans, trans)-1-
fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene], Aβ
antibody plus Thioflavin-S, and Aβ antibody plus Thioflavin-
T. Six anti-Aβ clones were used, with three of them against
the mid-portion of Aβ, two against C-terminus, and one
against N-terminus. Only three studies differentiated definite AD
patients from possible or probable AD patients. The median age
in Schön’s research (56 years old) was substantially lower than
in other eligible literature (≥71 years old). The characteristics
of the included studies are presented in Table 1. It should be
noted that samples of different staining methods from the same
study were usually identical. Whole mount retina was used in
FIGURE 1 | Flow chart of study selection.
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Koronyo-Hamaoui’s and Tsai’s while other three researches used
cross-section tissue.
The results of quality assessment are summarized in Table 2.
All of the eligible studies were labeled low applicability
concerns in every domain. However, they all shared the
same methodological limitations: insufficient information about
the exclusion criteria and whether blinding assessment was
employed, and case-control designs used without stating whether
the research recruited consecutive or random samples.
Results of Data Analysis
We classified the staining methods as immunolabeling and
fluorescent staining (with specific anti-Aβ compounds), and then
estimated Sen, Spe, PLR, NLR, DOR, and 95% CI by each
method category. We excluded Congo red staining data from
the analysis because it is not a specific compound of Aβ. If a
study had two or more data sets classified into a single method,
then the medians instead of the original data were employed for
analysis.
The estimates of Sen and Spe were extremely varied (from
0.00 to 1.00 for Sen, and 0.50 to 1.00 for Spe) with a wide 95%
CI. The estimate results were detailed in a forest plot (Figure 2)
and a ROC plot (Supplementary Figure S4). If more than one
study applied a certain kind of staining method (in this review,
immunostaining with and without the inclusion of probable or
possible AD patients, and fluorescent staining for all types of
AD patients), we included those studies in the data synthesis.
However, due to substantial heterogeneity and the small number
of included studies, the data synthesis results are presented in
Supplementary Figures S1–S3 instead, and were not taken into
account when drawing the conclusions.
The estimates of PLR, NLR, and DOR were also varied
extremely (from 0.71 to 11.57 for PLR, from 0.04 to 1.11 for NLR,
from 0.69 to 297.00 for DOR) with wide 95% CI. The estimate
results were detailed in a forest plot (Figures 3–5). Data synthesis
of these 3 measures failed because there were too many zeroes
in the data sets and the number of available studies was too
small.
TABLE 1 | Characteristics of included studies.
Study Reference
standard
Staining
method
Anti- Aβ clone (targeted
amino acid residues)
dAD
only
Number of
subjects
Median
age
Gender
(female:male)
Koronyo-Hamaoui et al., 2011 B, C, N Abs,
Abs+C
Abs+T-S
6E10 (1–16)
DE2B4 (1–16)
4G8 (17–24)
11A5B10 (34–40)
12F4 (36–42)
Yes
No
13
18
79.0
79.0
4:9
7:11
Schön et al., 2012 B, C Abs
Abs+FSB
Abs+T-S
4G8 (17–24) No 10 56.5 3:7
Ho et al., 2014 B, C CR 6F3D (8–17) Yes 15 79.0 11:4
Abs No 17 82.0 12:5
Tsai et al., 2014 B, C, N Abs 6E10 (1–16) No 12 80.0 6:6
Abs+T-T 4 79.0 −
La Morgia et al., 2016 B, C, N Abs 6E10 (1–16) Yes 10 73.8 5:5
Abs, C, CR, FSB, T-S, T-T in index test column refer to antibodies, curcumin, Congo red, (trans, trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene,
Thioflavin-S, and Thioflavin-T, respectively; B, C, N from reference standard refer to the Braak, the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD),
and the National Institute for Aging and Ronald and Nancy Reagan Institute for the Alzheimer’s Association (NIA-RIA) criteria, respectively; dAD, is the abbreviations of
definite Alzheimer’s disease.
TABLE 2 | Results of quality evaluation.
Study Risk of bias Applicability concerns
Patient
selection
Index
test
Reference
standard
Flow and timing Patient
selection
Index
test
Reference
standard
Koronyo-Hamaoui et al., 2011
Schön et al., 2012
Ho et al., 2014
Tsai et al., 2014
La Morgia et al., 2016
Low Risk High Risk Unclear Risk.
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FIGURE 2 | Forest plot of data analysis results of sensitivity and specificity.
Results of Heterogeneity Investigation
The meta-regression approach, with target population (definite
AD only or all types of AD), tissue preparation (whole
mount or cross section), staining methods (immunolabeling or
fluorescent staining), sex ratio (female:male), median age as
an independent variable and DOR as dependent variable, was
employed to investigate the sources of heterogeneity using a
random model.
For target population, meta-regression was conducted only
using paired data sets from studies including both kinds of
target population (Koronyo-Hamaoui’s and Ho’s) to reduce the
influence of between-study confounding factors. Only those data
sets using immunolabeling were included, in order to exclude
the impact of different staining methods, and fluorescent staining
data were not used since Ho’s study did not employ this method.
The coefficient was 0.20 with a p-value of 0.943.
For the staining methods, meta-regression was performed
among paired data sets from studies utilizing both immuno-
staining and fluorescent staining (Koronyo-Hamaoui’s, Schön’s,
and Tsai’s). The coefficient was 0.39 with a p-value of 0.84.
For tissue preparation, gender ratio, and median age, we only
included data sets using immunolabeling for all types of AD
patients, in order to reduce the influence of staining methods
or other confounding factors. These categories of data sets
FIGURE 3 | Forest plot of data analysis results of positive likelihood ratio.
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FIGURE 4 | Forest plot of data analysis results of negative likelihood ratio.
FIGURE 5 | Forest plot of data analysis results of diagnostic ratio.
were selected because they contained the largest sample sizes.
Logarithmic transformation was applied before the analysis of
gender ratio data. The estimates of coefficients were −2.78, 1.11,
and−0.04, and the estimates of p-values were 0.09, 0.65, and 0.75
for tissue preparation, gender ratio, and median age, respectively.
By visual inspection of the DOR forest plot, we found that for
a certain study using a certain kind of AD population, different
staining methods did not change the estimate results with only
one exception (Tsai’s).
DISCUSSION
Main Findings
The primary goal of this meta-analysis review was to determine
the ability of pathological detection of Aβin the retina to
diagnose AD. Although some studies have recently shown
promising outcomes with ocular Aβtests for AD diagnosis (Frost
et al., 2014; Kerbage et al., 2014), the results were relatively
disappointing in this review. The most promising results came
from Koronyo-Hamaoui’s study (Sen = 1.00, Spe = 1.00,
NLR ≤ 0.06, PLR ≥ 11.33, DOR ≥ 187.00) and La Morgia’s
study (Sen = 1.00, Spe = 1.00, NLR = 0.09, PLR = 11.00,
DOR = 121.00). Point estimates of the data set from Tsai’s
research using immunolabeling in all types of AD population
were less promising (Sen = 0.33, Spe = 1.00, NLR = 0.69,
PLR = 5.00, DOR = 7.22). Moreover, results from other data
sets showed that the accuracy of retinal Aβ detection was very
poor (Sen ≤ 0.45, NLR ≥ 1.00, PLR ≤ 1.00, DOR ≤ 1.00).
This inconsistency between studies and the significant statistical
heterogeneity indicated that there was still no conclusion to be
drawn about whether retinal Aβ detection is a suitable tool for
the diagnosis of AD.
Additionally, we aimed to investigate heterogeneity and
its sources. The quality assessment provided few clues about
heterogeneity source. The qualitative nature of the pathologic
tests did not support the hypothesis that threshold effects were
the main cause of the heterogeneity. Results of both visual
inspection and meta-regression did not support the idea that
staining method differences were a main source of heterogeneity.
The meta-regression approach provided little evidence except for
a trend in tissue preparation and such trend was not supported by
the result of visual inspection. It must be noticed that Koronyo-
Hamaoui used five antibody clones (against the N-terminus, the
mid-portion, or the C-terminus of the amino acid) to label Aβ,
while other four studies used only one clone (against either
the N-terminus or the mid-portion). The difference in anti-Aβ
is likely to contribute to the heterogeneity. Unfortunately, the
limited number of studies hampered us from confirming this
hypothesis and figuring out if the cause of heterogeneity lay in
the number of clones, the targeted locus, or other attributes of
these clones.
Limitations
Several factors limited this systematic review. The most notable
one was the small quantity of available studies, which had a
tremendous impact on the methods selected for pooled estimates
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and on the heterogeneity investigation, as well as an enormous
impact on the preciseness and reliability of our results. Another
limitation and a possible reason for the small number of eligible
studies was restricting the literature search to the English and
Chinese language. Although there is no sufficient evidence of
a systematic bias induced by language restrictions for meta-
analysis, and the quality of English-language studies may exceed
that of other languages, the inclusion of non-English research
would likely improve the precision of the outcome estimates
(Morrison et al., 2012). Third, subgroup analyses were not
utilized to explore sources of heterogeneity. And we failed to
investigate other potential sources, such as fixation chemistry
and application of antigen retrieval. Again, these limitations were
the consequence of the lack of eligible studies. Hence, it was
impossible to reach a satisfactory explanatory power via our
investigation of heterogeneity sources. Fourth, all eligible study
reported qualitative data instead of quantitative Aβ load that
could reveal more useful information.
Implications
This meta-analytic study suggested that for now evidences are not
sufficient to conclude whether pathological retinal Aβ detection
is an effective diagnostic tool for AD. Hinton reported a lack
of Aβ deposition in postmortem retinas of AD patients in 1986
(Hinton et al., 1986). Nevertheless, only a few studies have further
explored the relationship between AD and Aβ in the retina by
pathologic tests since then, while a great deal of effort has been
made to develop in vivo retinal Aβ detectors for the diagnosis of
AD. It is possible that the eager demand for novel non-invasive
diagnostic tools and the preference for positive results led to
this disparity that transgenic mouse models and in vivo human
research showed Aβ aggregation in the retina (Dutescu et al.,
2009; Perez et al., 2009; Alexandrov et al., 2011; Frost et al., 2014)
but only mixed results was found in postmortem human research.
The lack of postmortem retinal samples from AD patients may
also contribute to this inconsistency.
We hypothesized that, as in other fields of disease diagnosis,
pathological tests would be the golden standard for the detection
of Aβ, either in the brain or the retina, despite the fact that
in/ex vivo differences might affect the test results. Since autopsies
do not show considerable accuracy, for now, it may be worth
reconsidering the development of in vivo detection methods for
retinal Aβ. For instance, the differences in pathological changes
between AD patients and animal models may result in disparities
between clinical assessments and animal experiments, and the
ligands could be bound to other types of receptors that could be
falsely recognized as Aβ. A strong correlation between AD and
retina Aβ load must be demonstrated before we could consider
retina Aβ as a validated biomarker of AD and develop reliable
diagnostic tools base on retina Aβ detection.
We were unable to identify the main contributor to the
sharp discrepancy of results between studies. The variance
in research methodology, including sample characteristics and
labeling methods, was substantial and may strongly affect the
results. Based on very limited evidences, whole mount retinas
labeled by various antibodies that target both the terminus
and the mid-portion of Aβ seems to be the most promising
detection method. However, this is not conclusive and yet needs
to be tested. Thus the potential confounding factors mentioned
above, embedding methods, length of disease, or other possible
factors that were not considered in this study should be further
investigated in future research. Quantitative methods rather than
qualitative ones would be preferred. Consecutive or random
sample recruitment should be specified, blinding of results
between conductors of index tests and reference tests should
be employed if possible, and any exclusion criteria should be
described in detail.
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